The success of chemotherapeutic intervention is limited because the necessary high local drug doses cannot be achieved without systemic toxicity. Application of suicide genes (SGs) and direct conversion of prodrugs (PDs) to toxic metabolites in situ by SGs may enhance the efficacy of chemotherapy. To evaluate this strategy in two murine breast cancer models, TS/A and GR, we injected cellulose sulfate capsules harboring cat kidney cells expressing the SGs cytosine deaminase and cytochrome P450 2B1 (CYP2B1) intratumorally. The PDs 5-fluorocytosine and ifosfamide were administered in 3-day intervals. The effect of in situ chemotherapy with each PD alone and the combination was analyzed over a period of 100 days. The results reveal that for TS/A tumors, the antitumoral effect mediated by CYP2B1 is more efficient than that of cytosine deaminase, whereas for GR tumors, both systems worked equally well. Furthermore, we find additive toxicity using both SG/PD systems for both TS/A and GR tumors. Cancer Gene Therapy (2000) 7, 629 -636
T he transfer of suicide genes (SGs) into tumor cells is currently being used in a number of gene therapy trials for the treatment of localized, inoperable tumors. By far the most popular SG chosen for these trials is the thymidine kinase gene of herpes simplex virus (reviewed in Ref. 1) . Other SGs of potential therapeutic promise include the cytosine deaminase (CD) gene and some members of the cytochrome P450 family of enzymes. Regardless of the gene chosen, the strategy underlying SG therapy is to sensitize cells to prodrugs (PDs) by introducing genes encoding enzymes that convert these relatively nontoxic PDs into highly toxic metabolites. In a number of animal tumor models, it was shown that certain SG-modified cells can also mediate toxic effects on neighboring nonmodified cells, and that this "bystander killing effect" can be used to increase the efficacy of tumor therapy. 2 More recently, data from a clinical trial suggested that the bystander effect may provide a local and therapeutic antitumoral activity in the treatment of human brain tumors. 3 Furthermore, it was shown that, similar to conventional combination chemotherapy, two SG/PD approaches can be combined to synergistically enhance their antitumoral effects in vivo. 4, 5 Moreover, such a combinatorial approach should also provide a better means to deal with the problem of intrinsic or acquired drug resistance, which often accompanies chemotherapeutic intervention.
In this study two well-characterized SGs have been examined: (a) the CD gene of Escherichia coli and (b) cytochrome P450 2B1 (CYP2B1). CD converts the nontoxic compound 5-fluorocytosine (5-FC) to the toxic 5-fluorouracil, 6 which inhibits the synthesis of DNA and RNA processing. The CYP2B1 gene product activates oxaphosphorines, such as ifosfamide (IFO), to the hydroxy form, giving rise to the toxic products phosphamide mustard and acrolein, which alkylate DNA and proteins, respectively. The efficacy of each of the two SG/PD approaches has been shown in a number of in vitro experiments and in in vivo models (reviewed in Ref. 7) . The synergistic interaction of the pharmacologically active metabolites of these SG/PD systems has been well established 8 and has been applied in combination chemotherapy for many years. CYP2B1 and CD have been shown not only to kill transfected cells but also to exert toxic effects on neighboring cells. This bystander killing effect is due to the diffusible nature of the toxic metabolites. Both 4 hydroxy-IFO and 5-fluorouracil, are freely diffusible across cell membranes and thus can spread from gene-modified cells to adjacent nonmodified tumor cells. 9, 10 The aim of any SG/PD approach is to enhance the antitumoral effect by local activation of the PD. This should allow high therapeutically relevant levels of the active toxic products to be generated at the site of the tumor, in the absence of similarly high systemic levels that are associated with unacceptable dose-limiting toxicity. The success of such an approach depends upon the efficiency of the in vivo gene delivery system. However, the efficiency is further limited by factors such as the immunogenicity of the transfer vehicles as well as inappropriate regulation and expression of the therapeutic gene. Another strategy, which is based entirely on SG/PD approaches in which the toxic metabolites generated are freely diffusible, involves the implantation of genetically modified cells expressing the SG directly in or near to the tumor. To physically constrain the cells to the site of delivery and to limit immune responses raised against them, they can be encapsulated in cellulose sulfate polymers. This approach has been shown to be effective for human pancreatic tumor cells xenotransplanted into nude mice. 10 Here we show that (a) PDs locally activated by encapsulated cells can exert a local cytotoxic effect and kill mammary tumor cells, (b) the approach can be extended from one SG/PD system, CYP2B1/IFO, to a second system, CD/5-FC, and (c) the combined antitumoral activity of CY2B1/IFO and CD/5-FC is superior to a single SG/PD approach.
MATERIALS AND METHODS

Cell lines
TS/A murine mammary adenocarcinoma cells 11 and CRFK feline kidney cells 12 were cultured in RPMI 1640 medium. FLYA retroviral packaging cells 13 and GR murine mammary carcinoma cells 14 were grown in Dulbecco's modified Eagle's medium. All media were obtained from Life Technologies (Eggersheim, Germany) and supplemented with 10% heatinactivated fetal calf serum (Biochrom, Berlin, Germany).
Generation of CD-and CYP2B1-expressing CRFK cells
The vector pC3/2B1 was used to transfect the rat cytochrome CYP2B1 gene into CRFK cells. 10 A clone producing 7.6 ϫ 10 Ϫ17 mol resorufin/cell/30 minutes was transduced with the retroviral vector pBabeCD containing the E. coli CD gene and the puromycin resistance gene. 5 The obtained bulk culture (CRFK-2B1/CD) was cultured in the presence of 2.0 g/mL puromycin (Sigma, Deisenhofen, Germany) and used in all in vitro and in vivo experiments for the evaluation of single versus double SG/PD treatment.
In vitro cytotoxicity assays
The bioactivity of the SG products in CRFK cells was estimated by seeding 1 ϫ 10 3 CRFK-2B1/CD cells/well into a 6-well tissue culture plate (Costar, Cambridge, Mass) in 2 mL of medium. Alternatively, the bioactivity of the SG products produced from encapsulated CRFK-2B1/CD cells was evaluated by plating 1 ϫ 10 4 
Encapsulation of CRFK cells
Encapsulation was performed as described previously. 10 Briefly, 5 ϫ 10 8 gene-modified or parental CRFK cells were mixed with a total of 2.5% CsSO 4 in 5 mL of Dulbecco's phosphate-buffered saline (D-PBS) (BioWhittaker, Walkersville, Md) and 2-5% cellulose sulfate. The suspension was allowed to drop freely into a polymerizing solution consisting of 3% polydiallyldimethyl ammonium in D-PBS. The outer cellulose layers of the capsules polymerized immediately. The resulting capsules, with an average diameter of 0.5 mm, harbor ϳ1 ϫ 10 4 cells. They were washed twice with Dulbecco's modified Eagle's medium and then kept in tissue culture medium with 10% fetal calf serum until they were injected into the tumors.
In vivo experiments
Preformed tumors were established in BALB/c mice (Bomholtgard, Ry, Denmark) and GRmtv2 mice (breeding facility of the Institute of Virology, University of Veterinary Sciences, Vienna, Austria) by injecting 1 ϫ 10 6 TS/A or 5 ϫ 10 6 GR cells in 200 L of D-PBS subcutaneously into the left abdominal wall of 6-to 8-week-old female mice. Ten days after the inoculation of TS/A cells, when the tumors in BALB/c mice had reached a size of 4 -5 mm, and at 42 days after the inoculation of GR cells, when GR tumors were 7-8 mm in diameter, 70 -80 capsules harboring SG-expressing cells or nonmodified CRFK cells were injected into the tumors. The relevant PDs were administered intraperitoneally 24 hours after injection of the capsules. The following single and combined PD concentrations were applied in 3-day intervals throughout the experiment: 5-FC, 500 mg/kg; IFO, 100 mg/kg; 5-FC ϩ IFO, 500/100 mg/kg. Along with IFO, the uroprotective agent sodium-2-mercapto-ethanesulfonate (MESNA) (ASTA Medica) was coadministered intraperitoneally at a concentration of 50 mg/kg. The dose we used in our animal model did not show any overt toxicity as judged by a 4-week control experiment in which animals were treated identically to the tumor-bearing animals. None of the animals in the control groups showed weight loss. Tumor size was monitored at 3-day intervals for up to 100 days by measuring two disparate diameters using calipers. Animals were sacrificed at day 100 or when tumors reached 1.5 cm in diameter, and the tumors were excised and analyzed histologically. It is highly unlikely that tumors of 1.5 cm in the mouse will regress; therefore, for survival analysis, animals with tumors of this size were scored as having succumbed to the tumor. The numbers of animals in the experimental groups are indicated in Table 2 . All experiments were performed according to the European guidelines for animal experimentation.
Histology
Three mice with GR tumors and nine mice with TS/A tumors were histologically investigated at 3-11 weeks after injection of capsules. Immediately after euthanasia, subcutaneous tumors were resected and fixed for 24 hours in 7% neutral-buffered formalin. Tumor nodules were bisected, one part was processed for paraffin embedding, and 3-m thick serial sections were stained with hematoxylin and eosin.
RESULTS
Characterization of encapsulated SG-expressing cells
The CYP2B1 gene was transfected into CRFK cells and the CD gene was introduced into these cells by retroviral transduction to produce the cell line CRFK-2B1/CD. The biological activity of both SGs was evaluated by examining the sensitivity of CRFK-2B1/CD cells toward the respective PDs individually and in combination. As shown in Figure 1 , a 7-day PD treatment with 5-FC and/or IFO resulted in the death of a substantial number of CRFK-2B1/CD cells at relatively low PD concentrations (filled symbols), whereas nonmodified CRFK cells showed very little cell killing, even at the highest concentrations of PD (open symbols). Each of the individual SGs/PDs was very effective at reducing the survival of CRFK-2B1/CD cells in vitro. A combination of 5-FC and IFO resulted in maximal cell killing (Fig 1, solid line, F) even at the lowest PD concentration (100 g/mL 5-FC and 52 g/mL IFO), whereas this efficiency of cell killing could not be achieved with IFO even at concentrations that were eight times higher (416 g/mL) (Fig 1, dashed line, ࡗ), and could only just be achieved with 5-FC when concentrations were seven and a half times higher (750 g/mL) (Fig 1, dashed/dotted line, f) . The differences for the application of a combination of 5-FC ϩ IFO versus a single PD application are significant at low PD concentrations (100 g/mL 5-FC, 52 g/mL IFO ϩ 250 g/mL 5-FC, 104 g/mL IFO; P values of Ͻ0.0004), whereas differences were not significant at higher PD concentrations, as judged by the Student t test.
To investigate the bystander killing effect of encapsulated CRFK-2B1/CD cells mediated by the diffusible metabolites in vitro, TS/A and GR cells were cocultured with 30 capsules harboring CRFK-2B1/CD or nonmodified CRFK cells. PDs were added at individual concentrations (IFO at 52, 104, 208, 416, and 832 g/mL; 5-FC at 100, 250, 500, 750, and 1000 g/mL) and combined concentrations (IFO/5-FC at 52/100, 52/250, 104/250, 104/500, and 52/750 g/mL). A combination of IFO ϩ 5-FC was always more effective in killing tumor cells. For example, incubation of either mammary tumor cell line for 1 week with PDs and the capsules containing parental nonmodified CRFK cells (Fig 2., Ⅺ) resulted in little cytotoxic effects on TS/A (Fig 2A) and GR (Fig 2B) tumor cells, regardless of whether 5-FC and IFO were added individually or in combination. When capsules harboring CRFK-2B1/CD cells were cocultivated with TS/A cells (Fig 2A) , marked killing of the tumor cells was induced upon administration of either PD alone or a combination of both PDs (Fig 2, f) . Administration of the PDs resulted in killing of 84% or 54% of the tumor cells when doses of 250 g/mL 5-FC or 104 g/mL IFO in cell culture were used for 1 week, respectively. In combination, the same concentrations eliminated 93% of the TS/A tumor cells, demonstrating the superiority of a double PD approach in vitro (Fig 2A) . Cocultivation of GR cells and encapsulated CRFK-2B1/CD cells (Fig 2B) and addition of either PD yielded similar results (75% killing with 5-FC and 55% with IFO). A combination of the two PDs under identical conditions killed 91% of GR cells. Nonspecific toxicity (i.e., toxic effects on GR and TS/A cells alone) was observed for both GR and TS/A cells at individual concentrations of Ͼ260 g/mL IFO and 750 g/mL 5-FC and with a PD combination concentration of Ͼ208 g/mL IFO together with 500 g/mL 5-FC (data not shown). Differences for IFO alone compared with the double approach are statistically significant, whereas those for 5-FC are not, as judged by the Student t test.
Treatment of mammary tumors
To investigate whether combined in situ activation of PDs results in an antitumoral effect in vivo, TS/A or GR cells were injected into the corresponding syngeneic mice and allowed to establish tumors of 5-mm (TS/A) or 8-mm (GR) mean diameter. Capsules harboring either nonmodified CRFK or CRFK-2B1/CD cells were injected into the preformed tumors, and animals were treated systemically with the PDs individually or in combination at 3-day intervals.
When CRFK-2B1/CD cells were encapsulated and injected into TS/A tumors, the rate of tumor growth in the absence of PD treatment (Fig 3B, dotted line, ϫ, 
mm day
Ϫ1
) was not significantly different from the growth rate of nonmodified CRFK cells in the presence of IFO (Fig 3A, dashed line ). The difference in tumor growth at each data point was analyzed by linear regression (r) and the significance was determined from the number of mice per group and from P values ( Table 1) . These results indicate that the nonspecific toxicity of the PDs is negligible at the concentrations (500 mg/kg 5-FC and 100 mg/kg IFO) used in the TS/A system. The same analysis was performed for the GR system (Fig 3D, dotted line, (Table 1) to the growth of GR tumor cells in the presence of gene-modified CRFK-2B1/CD cells and no PDs. Because this is a growth-promoting, nonspecific effect of the PDs, it should only serve to increase the stringency of the GR model in revealing any antitumoral effect.
In contrast, tumor outgrowth, as judged by data point difference linear regression analysis was significantly slower (Table 1) in both tumor models when genemodified encapsulated CRFK-2B1/CD cells were injected intratumorally (Fig 3, B and E) and the animals were treated systemically with either a combination of both PDs or IFO alone. The rate of tumor growth for TS/A tumors treated with IFO alone (Fig 3B, dashed line, ࡗ) was slowed to 0.21 mm day
; a further decrease in growth rate was observed with both PDs (Fig 3B, solid  line, F) , to 0.08 mm day
. A similar reduction in growth was observed for the GR tumors ( Fig 3D) ; however, the reduction in growth rate observed with IFO (Fig 3D,  dashed line, ࡗ) to 0.07 mm day Ϫ1 was not significantly different from that obtained with a combination of 5-FC and IFO (Fig 3D, solid line, F, 0 .06 mm day Ϫ1 ). Treatment with encapsulated SG-modified cells and 5-FC reduced the rate of tumor growth only in the GR tumor model (Fig 3D, dashed/dotted line, f) . Here the reduction in growth rate to 0.04 mm day Ϫ1 was slightly more than that observed for the combination IFO and 5-FC (Fig 3D, solid line, F, 0 .06 mm day Ϫ1 ), although this difference is not statistically significant as judged by data point difference linear regression analysis (Table 1) . Treatment with 5-FC showed no effect on the growth rate of TS/A tumors treated with encapsulated modified cells (Fig 3B, dashed/dotted line, f) .
Correlating with the rate of tumor outgrowth, the combination of PDs always resulted in the best survival (Table 2) . Encapsulated CRFK-2B1/CD cells in conjunction with dual PD treatment more than doubled the survival time (44 days for TS/A and 36 days for GR) in comparison with the control groups (groups 1-4 in Table 2 survived on average 14 -20 days) for both tumor models. Treatment of TS/A tumors with IFO in combination with nonmodified encapsulated CRFK cells increased survival times slightly, presumably due to endogenous activation of this PD by cytochrome P450 enzymes expressed in the liver. However such an effect was not seen in the GR model, and any such endogenous activation was not as effective as in situ activation of the PD by encapsulated SG-modified cells. For example, in TS/A tumor-bearing animals, the mean survival of animals treated with nonmodified CRFK cells plus IFO was 20 days, whereas in the mean survival of animals treated with CRFK-2B1/CD plus IFO was 32 days. Taken together, the results obtained in the GR tumor model correlated very well with those obtained in the TS/A model. However, in the TS/A model, the combination of encapsulated CRFK-2B1/CD cells treated with IFO and 5-FC was most effective in increasing survival in the experimental groups and even led to one tumor-free animal.
Histology
To ensure the physical localization and integrity of the capsules in the tumors and to rule out the possibility that inflammatory processes were induced by the capsules or the surgical procedure of implanting the capsules, tumors were excised and analyzed histologically after PD treatment.
Macroscopically, both tumor types were compact firm grayish nodules that were well delimited and moderately attached to the surrounding connective tissue. The TS/A tumors showed a necrotic center, even without capsule application. Histological analysis revealed that capsules often showed marked deformation due to mechanical stress during tumor growth and/or histological processing. In no case was there any sign of capsule rupture. Three different histologies were observed for the TS/A tumors after capsule implantation and PD activation, listed in order of frequency: (a) the capsules were embedded in a large mass of necrotic tumor tissue, without evidence of an inflammatory response; (b) the capsules were surrounded by or infiltrated with neutrophilic granulocytes; (c) in one case, some of the capsules lay at the tumor periphery, causing a slight lymphocytic and fibroblastic reaction, whereas some capsules in the tumor center caused no tissue reaction. In GR tumors, the capsules were surrounded either by a thin seam of necrotic tumor cells or by fibrous tissue with some multinucleated giant cells. 4, 5 In these tumor models, a double SG/PD approach was always more effective in eradicating tumor cells. To further improve this double SG/PD strategy, we have chosen to combine a new pair of SGs, CD with CYP2B1. The synergistic interaction of the toxic metabolites of these two SG/PD approaches has been wellestablished and is used in the clinic for combination chemotherapy. To improve a possible clinical application, SG-expressing cells were encapsulated to protect them from destruction by the immune system and to physically localize them to the tumor. This strategy should allow the local delivery of the toxic metabolites without the limitations associated with in vivo gene delivery. The delivery of toxic metabolites by SG-modified encapsulated cells is a potentially safer and more feasible approach for localized solid tumor therapy than direct gene therapeutic intervention with living or irradiated packaging cells releasing retroviral vector particles. 3 The encapsulated cells themselves appear to show reduced sensitivity to the S phase toxicity of the activated metabolites they produce, probably because they are limited in their potential to proliferate as a result of spatial restrictions within the capsule. The feasibility of the encapsulated SG/PD approach has been demonstrated previously in a pancreatic tumor model and depends upon the ability of the activated PD to exert toxic effects on neighboring cells by diffusion of the toxic metabolite. 10 In vitro, encapsulated cells expressing CD and CYP2B1 exerted cytotoxic effects on cocultured mammary tumor cells (TS/A, GR) upon administration of the respective PDs. At relatively low PD concentrations, a combination of both SG/PD approaches was effective in killing cocultured tumor cells.
Treatment of pre-established tumors with PDs and encapsulated SG-modified cells leads, with the exception of 5-FC treatment of TS/A tumors, to a significant reduction in tumor growth rate and a marked increase in survival time. Even though CD/5-FC showed no therapeutic effects when used alone for the treatment of TS/A tumors, it nevertheless enhanced the efficacy of treatment when used in combination with IFO. Other investigators have shown that 5-FC is effective for the treatment of TS/A tumors pre-engineered to express CD. 15 One explanation for the diminished responsiveness of TS/A tumors to 5-FC in our model system might be that local concentrations of the PD may not have been high enough or that the preformed tumors may have been too large when treatment was started. CD/5-FC has been used successfully to treat TS/A tumors only when tumors were Յ2 mm in diameter. 5, 15 It is also likely that the success of the system reported by Consalvo et al 15 was a result of using exclusively CD-expressing TS/A tumor cells, thus ensuring the best possible antitumoral effect. A double SG/PD approach using CD and CYP2B1 showed the greatest efficacy in the treatment of both TS/A and GR tumors. The feasibility of double SG/PD approaches also has been shown in other models, 4,5 but never for the combination of rat cytochrome CYP2B1 and CD.
The encouraging data obtained with both SG/PD approaches in vitro, did not translate into complete tumor eradication. This is probably due to the late start of PD treatment, to the fact that we were purely relying on the bystander effect when using capsules, and last but not least to the obvious fact that a single layer of cells in culture is much more accessible to the diffusible toxic metabolites than a compact solid tumor. However, for technical reasons, tumors have to reach a certain diameter before capsules can be implanted, and because we believe that large tumors more closely reflect the envisaged clinical setting in which SG/PD approaches are used, we chose to start PD treatment when tumors were fairly large.
Histology revealed a good physical localization and integrity of the capsules in the tumors, and even though the cellular environment reacted slightly differently toward the implanted capsules, the antitumoral effect was very similar in both tumor models. Clear differences, however, could be observed between mice treated with PD and nonmodified CRFK cells and those treated with gene-modified CRFK cells and PD. Thus, we conclude that the direct tumoricidal activity of the toxic metabolites released by the encapsulated cells, rather than the cellular response to the capsules, is responsible for this difference. This is supported by our previous studies in a nude mouse model of pancreatic cancer. 10 Taken together, our experiments confirm that it is possible to enhance the antitumoral effect by local activation of PDs using encapsulated cells; furthermore, we also found that a double approach (CY2B1/IFO and CD/5-FC) is superior to a single SG/PD approach. However, the system needs to be further improved in its efficacy. 
